ZCCHC4 and cancer: Antisense oligonucleotides (ASOs) and small molecule compound are main strategies for targeting RBPs, whose efficiency and operability have been validated by many preclinical and clinical researches.38,39 Our study showed that high expression of ZCCHC4 was related with shorter survival in multiple cancer types and that intratumoral targeting ZCCHC4 could significantly improve the antitumor effect of chemotherapy in mice bearing inoculated HCC.